AstraZeneca is a global patient-oriented biopharmaceutical company focused on the research, development, and expansion of access to medications primarily in therapeutic areas such as oncology, cardiology, nephrology, metabolic disorders, respiratory and autoimmune diseases, as well as rare diseases. For over 100 years, AstraZeneca has been developing and producing innovative pharmaceutical products that expand the possibilities of modern medicine and improve patients' lives. AstraZeneca is among the top 5 international biopharmaceutical companies engaged in research and production of prescription medicines in more than 100 countries. Millions of patients worldwide use innovative products manufactured by AstraZeneca.
AstraZeneca's representative office in Kazakhstan was opened in 2007. Currently, the company employs over 220 people across more than 19 cities in the country, including Almaty, Astana, Karaganda, Shymkent, Aktobe, Ust-Kamenogorsk, Uralsk, and others. In 2024 and 2025, the company was recognized as the best employer by the Top Employer Institute. Currently, there are about 30 AstraZeneca products registered in Kazakhstan in therapeutic areas such as oncology, respiratory and autoimmune diseases, cardiovascular diseases, and metabolic disorders.
In September 2023, a Limited Liability Partnership "AstraZeneca Kazakhstan" was registered in Kazakhstan, marking the beginning of a new stage of the company's development in the Republic. The registration of a local legal entity with its own warehouse will allow AstraZeneca to increase its business presence in Kazakhstan, become a more attractive partner for distributors and government bodies, and expand access to innovative therapy for millions of patients in Kazakhstan.

Novartis is an international pharmaceutical company headquartered in Basel, Switzerland. Novartis is working by rethinking the approach to medicine to improve the quality and longevity of people's lives. As a leading international pharmaceutical company, we apply the latest scientific achievements and digital technologies to create innovative drugs to solve the most pressing medical and social problems. For many years, Novartis has been at the top of international rankings of companies investing in research and development. Our products reach more than 250 million people around the world each year, and we are constantly working to find innovative solutions to increase patient access to the therapies they need. The Novartis group of companies employs approximately 78,000 employees representing more than 140 nationalities.

GEROPHARM is an international producer of biotechnology products and a reliable partner in terms of medicinal security in the EAEU countries.
The Company specialises in neurology, endocrinology, ophthalmology, gynaecology, and urology. Currently, GEROPHARM portfolio includes original medicinal products, biosimilar recombinant human insulins and insulin analogs, and generics. In total it is 35 products, including 11 ultra-rapid-, rapid-, intermediate-, and long-acting insulins.
GEROPHARM tops the Russian insulin market and is among the top 10 insulin manufacturers in the world. The Company runs all production stages at its own facilities in Russia, complying with international GxP standards.
In October 2023, GEROPHARM registered Semavic®, Russia's first Ozempic® analog, and issued Semavic®Next, the second product for obesity treatment, similar to Wegovy, in 2024.
Currently, its R&D centre is developing an original innovative ultra-long-acting insulin with a week-long action profile, which is globally peerless.
Medicinal products of the Company are represented in 14 other countries.

R-Pharm Group introduces comprehensive solutions for the healthcare system and focuses on research, development, manufacturing and commercialization of pharmaceuticals, laboratory equipment and medical devices. R-Pharm's mission is to increase the accessibility of advanced diagnostics, preventative care and therapy methods in Russia and abroad.
More than 5000 employees of the group do their best to provide as many people as possible with the necessary means to improve and prolong their lives.
R-Pharm’s 11 state-of-the-art manufacturing sites are functioning in accordance with international quality standards. The group has signed agreements on strategic partnership, production localization and technology transfer with the world's leading manufacturers of pharmaceuticals and medical equipment.
The most important activities of the group include research and development. Today, R-Pharm’s research pipeline contains more than 100 knowledge-intensive products, many of which are capable of making a serious contribution to the fight against high burden diseases.
Following corporate social responsibility policies, R-Pharm organizes projects aiming to increase awareness about dangerous diseases, promote healthy lifestyle, improve the educational system and foster a new generation of professionals in the pharmaceutical industry.

VERBA LEGAL is a Russian law firm with an international expertise. We provide services on a wide range of legal issues, using the best SERVICES in combination with international professional standards.

GRATA International is a dynamically developing international law firm that services projects in 23 countries worldwide, offering services in 18 areas of law and 8 sectors of the economy. The office network provides the most comprehensive coverage of the Eurasian region. The firm's team consists of more than 200 professionals trained to manage cross-border projects. The firm's reputation and experience are confirmed by reviews from multinational clients and leading international rankings, such as Chambers and Partners, The Legal 500, IFLR, and others.

AEQUITAS Law Firm was founded in 1993 and is now among the top Kazakhstan firms recognized on the global legal services market. The top influential ranking agencies, such as Chambers & Partners, The Legal 500, Lexology, and other rank AEQUITAS and its lawyers among the most sought-after experts.

In 2021, 2022, 2023 and 2024, AEQUITAS was awarded as the Firm of the Year in Kazakhstan following the results of Lexology Index Awards (former Who’s Who Lega Awards) organized by Lexology, international ranking agency.

AEQUITAS is active in rendering expert legal services in the sphere of healthcare, medicine and pharmaceuticals.

AEQUITAS clients are the companies from the leading economy sectors from more than 50 countries, which include 20 international, foreign and Kazakhstan companies manufacturing medical and pharmaceutical products, as well as the largest international corporations and companies representing the world-famous brands, banks and financial institutions.
Our core values are high quality of services, honesty, transparency, and efficiency.

LLC "Muse Media", founded in 2017, is the exclusive supplier of NOW Foods, MRM Nutrition, Webber Naturals products in Russia and the winner of the "Platinum Ounce" 2022, the All-Russian open competition for pharmaceutical industry professionals.

NOW Foods produces over 3,500 products (including 900 dietary supplements), recognized in more than 80 countries worldwide, certified by GMP, and meeting the necessary FDA requirements. MRM Nutrition provides high-quality nutrition to consumers worldwide, offering dietary supplements for overall well-being, high sports performance, as well as options for vegans and vegetarians. Webber Naturals manufactures supplements free from artificial colors, sweeteners, GMOs, and gluten. The Sesame Street children's product line is an exclusive range that has long established itself in Canada.

By promoting these products, Muse Media advocates for a responsible approach to health and offers solutions to improve quality and longevity of life.

For over 25 years, Proxima Research has developed products and services in the healthcare sector, enabling clients to achieve new levels of business efficiency.

The company provides expert solutions in market data, CRM/ETMS integration and support, HCP/HCO database management, omnichannel marketing, BI solution implementation, market research, and consulting, with a strong focus on the pharmaceutical industry.

Proxima Research operates based on three core principles:
• Innovation: Continuously exploring new opportunities to develop cutting-edge solutions that drive industry growth.
• Quality: Ensuring that research and products meet the highest standards while taking full responsibility for every aspect of its operations.
• Results: Combining technology, in-depth research, and business expertise to achieve tangible outcomes that help clients expand and thrive.

For more information, visit company website: https://proximaresearch.com/kz/en/

Компания Aston Health сегодня – это современные технологии и проверенные данные для решения бизнес-задач фармпроизводителей, дистрибьюторов, аптечных сетей, медицинских и пациентских сообществ, государственных учреждений и профессиональных ассоциаций, работающих на рынке здравоохранения.

С 1999 года деятельность компании посвящена изучению, систематизации и развитию этого рынка. Мы хорошо понимаем его механизмы, оцениваем все составляющие и предвидим тенденции развития.

Основные направления работы:

• Мониторинговые программы пациентов
• Диагностические программы и подбор пациентов
• Маркетинговые исследования, GR и Market Access программы
• Программы поддержки пациентов
• Образовательные программы для врачей и пациентов
• Анализ и экспертиза фармацевтического рынка

DEVA Holding is the well-established pharmaceutical manufacturers in Türkiye since 1958. With the main area of operations including manufacturing and marketing medicinal products for human, also manufactures veterinary medicines, eau de Cologne, and medical ampoules.

Currently, its product portfolio contains more than 650 products in 14 therapeutic areas.
With progressively expanding regional growth and export operations, DEVA Holding is the holder of 1,119 marketing authorizations in 65 countries, including the USA, Switzerland, Germany. Founded under the brand name of Devatis in Germany and Switzerland, the company received registration approval in 2018 and having been established in the USA under the same name, accelerated its activities. Currently exports pharmaceuticals and pharmaceutical raw materials to more than 60 countries.

DEVA Holding focuses on R&D to improve access to medicines for patients, and all of its manufacturing facilities are certified compliant with the European GMP and US FDA.
DEVA Holding develops high-quality and innovative products with its award-winning R&D center, strong staff of well-trained employees who are experts in their respective fields, and full-fledged laboratories and manufacturing sites equipped with cutting-edge technology.

Undertaking manufacturing operations at facilities in Çerkezköy and Kartepe, DEVA Holding holds an annual output capacity of 620 million units of medicines.